© 2005 Master Publishing Group
Original Article [FullText] [PDF]

## Neutralization of IL-4 and IFN-γ Facilitates inducing TGF-β-induced CD4+Foxp3+ Regulatory Cells

Xiaojuan Tao<sup>1</sup>, Jilin Ma<sup>1</sup>, Yonghua Zhang<sup>1</sup>, Jianning Yu<sup>1</sup>, Long Cai<sup>1</sup>, Juhua Wang<sup>2</sup>, Song Guo Zheng<sup>2</sup>

1 Division of Rheumatology, Immunology and Nephrology, Zhejiang Traditional Chinese Medicine and Western Medicine Hospital, Hangzhou, People' s Republic of China

2 Division of Rheumatology and Immunology, Department of Medicine, University of Southern California, Keck School of Medicine, Los Angeles, USA

Corresponding Author: Song Guo Zheng, 2011 Zonal Ave. HMR 710A, Los Angeles, CA 90033, USA. Tel: 323 442 2128; Fax: 323 442 2874; E-mail: szheng@usc.edu.

suppressor/regulatory T cells, cytokine, Foxp3, autoimmunity

It has been well recognized that TGF- $\beta$  is able to induce CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> suppressor/regulatory T (iTreg) cells and IL-2 facilitates iTreg induction and expansion, however, only half of TGF- $\beta$ -induced CD4<sup>+</sup>CD25<sup>+</sup> cells express Foxp3 and remaining CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>-</sup> cells may represent effector cells. Whether other factor(s) can increase Foxp3 expression by CD4<sup>+</sup>CD25<sup>+</sup> cells induced with TGF- $\beta$  is still unclear. Here we show that addition of exogenous IFN- $\gamma$  or IL-4 diminished the ability of TGF- $\beta$  to induce Foxp3 expression and IL-2 failed to rescue this decreased Foxp3 expression. Conversely, neutralization of IFN- $\gamma$  and IL-4 significantly enhanced the ability of TGF- $\beta$  to induce Foxp3 and develop the suppressive activity, indicating that different cytokine profiles affect the differentiation of CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> subset induced by TGF- $\beta$ . These results show that combination of antibodies against IFN- $\gamma$  and IL-4 and TGF- $\beta$  enhances the efficacy of generation and function of iTreg cells and may therefore provide a novel therapeutic strategy for the treatment of autoimmune and other chronic inflammatory diseases.

 Master Publishing Group

 328 N. Moore Avenue, Monterey Park, CA 91754, USA

 Tel:1-626-943-7985, Fax:1-626-282-8693, Email editor & the org

 Feedback | About IJBS | Contact Us | Subscription

 Copyright © 2005 by the Master publishing Group